SAN DIEGO--(BUSINESS WIRE)--RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced that the Company will be presenting data for its lead clinical program, RYZ101 (Ac225 DOTATATE) at two upcoming medical conferences as well as presentations on preclinical programs.
2023 American Society for Clinical Oncology (ASCO) annual meeting: June 2 - 6 in Chicago, IL
Title: ACTION-1 phase 1b/3 trial of RYZ101 in somatostatin receptor subtype 2–expressing (SSTR2+) gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Initial safety analysis.
Abstract #: 4132
Presenter: Jonathan Strosberg
Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Date/Time: 6/5/2023, 8:00 AM-11:00 AM
Australian and New Zealand Society of Nuclear Medicine (ANZSNM): May 26 - 28 in Adelaide, Australia
Title: Anti-tumor activity of RYZ101 in somatostatin receptor-expressing preclinical models of small-cell lung cancer.
Presenter: Jessica Rearden
Session Title: Poster Session
Date/Time: Saturday May 27th / 1-130pm
Title: Novel peptide binder to Glypican-3 for targeted radiopharmaceutical therapy of hepatocellular carcinoma.
Presenter: Ken Song
Session Title: Oral Presentation
Date / Time: Saturday May 27th / 5:15 – 5:30pm
RYZ101 is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), to tumors expressing SSTR2. RYZ101 is being evaluated in clinical studies for patients with SSTR+ GEP-NETs who have previously been treated with Lu177-based somatostatin therapies and also in patients with extensive stage small cell lung cancer. Details of the studies can be found at https://clinicaltrials.gov/ct2/show/NCT05477576 and https://clinicaltrials.gov/ct2/show/NCT05595460.
Ac225 for the study was provided by multiple sources including the U.S. Department of Energy Isotope Program.
RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020. For additional information, please visit www.rayzebio.com.